MedTrace Logo

Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

NCT05414747 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-11-18

No results posted yet for this study

Summary

A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of the ABV-1701 Ocular Endotamponade (OE)

Conditions

  • Retinal Detachment

Interventions

DEVICE

ABV-1701

ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH)

DEVICE

SF6 Gas

SF6 is a commercial gas tamponade as a vitreous substitute in pars-plana vitrectomy surgery (PPV)

Sponsors & Collaborators

  • ABVC BioPharma, Inc

    collaborator UNKNOWN

  • BioFirst Corporation

    lead INDUSTRY

Principal Investigators

  • Richard CH King, Ph.D. · ABVC BioPharma, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-15
Primary Completion
2024-12-15
Completion
2025-12-15

Countries

  • Australia
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414747 on ClinicalTrials.gov